The stock has a 36-month beta value of 1.05. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for LXRX is 179.90M, and at present, short sellers hold a 23.92% of that float. On February 25, 2025, the average trading volume of LXRX was 4.80M shares.
LXRX) stock’s latest price update
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX)’s stock price has plunge by -5.71relation to previous closing price of 0.70. Nevertheless, the company has seen a -13.20% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-18 that Data reinforce unique clinical advantages of sotagliflozin Published study is aligned with research presented in December 2024 at the American Society of Hematology showing clinical benefits of sotagliflozin compared to empagliflozin THE WOODLANDS, Texas, Feb. 18, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to reduce the risks of life-threatening cardiovascular outcomes. The findings from the study, “Reduction in Major Adverse Cardiovascular Events with Sotagliflozin: A Prespecified Analysis of the SCORED Randomized Trial,” concluded that the ischemic benefit of sotagliflozin on both heart attack (myocardial infarction, or MI), and stroke reduction has not been shown by other SGLT inhibitors.
LXRX’s Market Performance
Lexicon Pharmaceuticals Inc (LXRX) has seen a -13.20% fall in stock performance for the week, with a -33.12% decline in the past month and a -18.00% plunge in the past quarter. The volatility ratio for the week is 11.01%, and the volatility levels for the past 30 days are at 11.75% for LXRX. The simple moving average for the past 20 days is -11.67% for LXRX’s stock, with a -53.30% simple moving average for the past 200 days.
Analysts’ Opinion of LXRX
Many brokerage firms have already submitted their reports for LXRX stocks, with H.C. Wainwright repeating the rating for LXRX by listing it as a “Buy.” The predicted price for LXRX in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on June 17, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see LXRX reach a price target of $5. The rating they have provided for LXRX stocks is “Outperform” according to the report published on April 30th, 2024.
Jefferies gave a rating of “Hold” to LXRX, setting the target price at $3 in the report published on March 07th of the previous year.
LXRX Trading at -14.59% from the 50-Day Moving Average
After a stumble in the market that brought LXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.60% of loss for the given period.
Volatility was left at 11.75%, however, over the last 30 days, the volatility rate increased by 11.01%, as shares sank -27.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.59% lower at present.
During the last 5 trading sessions, LXRX fell by -9.41%, which changed the moving average for the period of 200-days by -62.24% in comparison to the 20-day moving average, which settled at $0.7510. In addition, Lexicon Pharmaceuticals Inc saw -10.35% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXRX starting from COATS LONNEL, who proposed sale 300,000 shares at the price of $1.60 back on Aug 15 ’24. After this action, COATS LONNEL now owns shares of Lexicon Pharmaceuticals Inc, valued at $480,000 using the latest closing price.
Stock Fundamentals for LXRX
Current profitability levels for the company are sitting at:
- -40.37 for the present operating margin
- 0.88 for the gross margin
The net margin for Lexicon Pharmaceuticals Inc stands at -41.09. The total capital return value is set at -0.74. Equity return is now at value -135.14, with -71.91 for asset returns.
Based on Lexicon Pharmaceuticals Inc (LXRX), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -2.05. The debt to equity ratio resting at 0.57. The interest coverage ratio of the stock is -12.32.
Currently, EBITDA for the company is -163.46 million with net debt to EBITDA at -0.33. When we switch over and look at the enterprise to sales, we see a ratio of 57.74. The receivables turnover for the company is 1.81for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.45.
Conclusion
To sum up, Lexicon Pharmaceuticals Inc (LXRX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
